Retour

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Stocks Earnings Releases and Operating Results

First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024

GlobeNewswire Inc. • 07/05/2024 à 13:01:00
Prelude Therapeutics Incorporated
Address: 175 INNOVATION BOULEVARD
Postal Code: 19805
City: WILMINGTON
State: DE
Phone Number: (302) 467-1280
Website: https://www.preludetx.com
Status: Active
Company Info

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

List Date2020-09-25
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001678660
Composite figiBBG00K7JY2Q6
Share Class figiBBG00K7JY2R5
Market Cap219,718,268 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees128
Share Class Shares Outstanding54930000
Weighted Shares Outstanding54929567
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
3.871
4.19
4.186
3.72
3.814
Variance
-7.61%
0.12%
8.45%
-2.49%
1.84%
Open
4.19
4.185
3.86
3.815
3.745
Highest
4.29
4.353
4.209
4.025
3.91
Lowest
4.25
4.308
4.202
4.02
3.91
History
PeriodVarhighestlowest
1 week
3.36%
3.91
3.91
1 month
1.57%
3.955
3.785
3 month
-19.42%
4.804
3.785
6 month
6.93%
3.62
2.62
1 year
-33.37%
5.81
1.66
3 year
-89.95%
39.62
1.66
5 year
-84.66%
29.49
1.66
10 year
-84.66%
29.49
1.66
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-03 2023-11-01 UNPUB
Assets 198,320,000 280,611,000 258,511,000 UNPUB
Current Assets 175,263,000 260,210,000 234,916,000 UNPUB
Current Liabilities 19,662,000 15,190,000 16,893,000 UNPUB
Equity 175,297,000 262,060,000 238,257,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 175,297,000 262,060,000 238,257,000 UNPUB
Liabilities 23,023,000 18,551,000 20,254,000 UNPUB
Liabilities And Equity 198,320,000 280,611,000 258,511,000 UNPUB
Noncurrent Assets 23,057,000 20,401,000 23,595,000 UNPUB
Noncurrent Liabilities 3,361,000 3,361,000 3,361,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-03 2023-11-01 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -12,404,000 8,245,000 -10,550,000 UNPUB
Net Cash Flow, Continuing -12,404,000 8,245,000 -10,550,000 UNPUB
Net Cash Flow From Financing Activities -269,000 111,339,000 88,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -269,000 111,339,000 88,000 UNPUB
Net Cash Flow From Investing Activities 17,999,000 -75,426,000 15,045,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 17,999,000 -75,426,000 15,045,000 UNPUB
Net Cash Flow From Operating Activities -30,134,000 -27,668,000 -25,683,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -30,134,000 -27,668,000 -25,683,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-03 2023-11-01 UNPUB
Comprehensive Income/Loss -26,424,000 -30,744,000 -30,502,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -26,424,000 -30,744,000 -30,502,000 UNPUB
Other Comprehensive Income/Loss 1,294,000 -30,744,000 -30,502,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-03 2023-11-01 UNPUB
Basic Earnings Per Share -1 -1 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -27,718,000 -30,431,000 -30,608,000 UNPUB
Income/Loss From Continuing Operations Before Tax -27,718,000 -30,431,000 -30,608,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -27,718,000 -30,431,000 -30,608,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -27,718,000 -30,431,000 -30,608,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -27,718,000 -30,431,000 -30,608,000 UNPUB
Operating Expenses 29,115,000 32,398,000 33,385,000 UNPUB
Operating Income/Loss -29,115,000 -32,398,000 -33,385,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-14 2023-03-15
Assets 280,671,000 259,055,000 242,327,000 220,500,000
Current Assets 269,972,000 248,624,000 226,893,000 204,380,000
Current Liabilities 16,069,000 15,811,000 21,560,000 21,702,000
Equity 261,812,000 240,844,000 217,407,000 195,437,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 261,812,000 240,844,000 217,407,000 195,437,000
Liabilities 18,859,000 18,211,000 24,920,000 25,063,000
Liabilities And Equity 280,671,000 259,055,000 242,327,000 220,500,000
Noncurrent Assets 10,699,000 10,431,000 15,434,000 16,120,000
Noncurrent Liabilities 0 0 3,360,000 3,361,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-14 2023-03-15
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 19,806,000 -928,000 1,316,000 -1,223,000
Net Cash Flow, Continuing 19,806,000 -928,000 1,316,000 -1,223,000
Net Cash Flow From Financing Activities 153,000 359,000 148,000 815,000
Net Cash Flow From Financing Activities, Continuing 153,000 359,000 148,000 815,000
Net Cash Flow From Investing Activities 41,548,000 17,181,000 21,607,000 81,691,000
Net Cash Flow From Investing Activities, Continuing 41,548,000 17,181,000 21,607,000 81,691,000
Net Cash Flow From Operating Activities -21,895,000 -18,468,000 -20,439,000 -83,729,000
Net Cash Flow From Operating Activities, Continuing -21,895,000 -18,468,000 -20,439,000 -83,729,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-14 2023-03-15
Comprehensive Income/Loss -29,465,000 -27,374,000 -30,027,000 -116,419,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -31,067,000 -27,355,000 -30,027,000 -116,419,000
Other Comprehensive Income/Loss 0 0 -30,027,000 -981,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-14 2023-03-15
Basic Earnings Per Share -1 -1 -1 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -29,465,000 -27,374,000 -29,958,000 -115,438,000
Income/Loss From Continuing Operations Before Tax -29,465,000 -27,374,000 -29,958,000 -115,438,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -29,465,000 -27,374,000 -29,958,000 -115,438,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -29,465,000 -27,374,000 -29,958,000 -115,438,000
Net Income/Loss Available To Common Stockholders, Basic -29,465,000 -27,374,000 -29,958,000 -115,438,000
Operating Expenses 30,288,000 29,461,000 30,406,000 123,540,000
Operating Income/Loss -30,288,000 -29,461,000 -30,406,000 -123,540,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-12 2021-11-12 2022-03-17
Assets 369,831,000 349,581,000 331,217,000 305,098,000
Current Assets 365,018,000 344,575,000 325,897,000 295,115,000
Current Liabilities 12,424,000 14,677,000 19,663,000 19,201,000
Equity 356,567,000 334,361,000 311,242,000 285,897,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 356,567,000 334,361,000 311,242,000 285,897,000
Liabilities 13,264,000 15,220,000 19,975,000 19,201,000
Liabilities And Equity 369,831,000 349,581,000 331,217,000 305,098,000
Noncurrent Assets 4,813,000 5,006,000 5,320,000 9,983,000
Noncurrent Liabilities 0 0 312,000 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-12 2021-11-12 2022-03-17
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 144,681,000 -19,871,000 -281,695,000 -182,437,000
Net Cash Flow, Continuing 144,681,000 -19,871,000 -281,695,000 -182,437,000
Net Cash Flow From Financing Activities 161,810,000 422,000 711,000 164,897,000
Net Cash Flow From Financing Activities, Continuing 161,810,000 422,000 711,000 164,897,000
Net Cash Flow From Investing Activities -986,000 -381,000 -260,632,000 -263,803,000
Net Cash Flow From Investing Activities, Continuing -986,000 -381,000 -260,632,000 -263,803,000
Net Cash Flow From Operating Activities -16,143,000 -19,912,000 -21,774,000 -83,531,000
Net Cash Flow From Operating Activities, Continuing -16,143,000 -19,912,000 -21,774,000 -83,531,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-12 2021-11-12 2022-03-17
Comprehensive Income/Loss -21,300,000 -26,865,000 -30,863,000 -112,405,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -21,300,000 -26,865,000 -30,863,000 -112,405,000
Other Comprehensive Income/Loss 0 0 -30,863,000 -711,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-12 2021-11-12 2022-03-17
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -21,300,000 -26,865,000 -30,687,000 -111,694,000
Income/Loss From Continuing Operations Before Tax -21,300,000 -26,865,000 -30,687,000 -111,694,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -21,300,000 -26,865,000 -30,687,000 -111,694,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -21,300,000 -26,865,000 -30,687,000 -111,694,000
Net Income/Loss Available To Common Stockholders, Basic -21,300,000 -26,865,000 -30,687,000 -111,694,000
Operating Expenses 21,967,000 27,922,000 30,836,000 113,735,000
Operating Income/Loss -21,967,000 -27,922,000 -30,836,000 -113,735,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-10 2021-03-16
Assets UNPUB UNPUB 239,681,000 223,590,000
Current Assets UNPUB UNPUB 238,061,000 220,809,000
Current Liabilities UNPUB UNPUB 11,359,000 11,375,000
Equity UNPUB UNPUB 228,307,000 212,183,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 228,307,000 212,183,000
Liabilities UNPUB UNPUB 11,374,000 11,407,000
Liabilities And Equity UNPUB UNPUB 239,681,000 223,590,000
Noncurrent Assets UNPUB UNPUB 1,620,000 2,781,000
Noncurrent Liabilities UNPUB UNPUB 15,000 32,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-10 2021-03-16
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB UNPUB 199,430,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 199,430,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 246,228,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 246,228,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -621,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -621,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -46,177,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -46,177,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-10 2021-03-16
Comprehensive Income/Loss UNPUB UNPUB -16,760,000 -56,929,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -16,760,000 -56,929,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-10 2021-03-16
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -16,760,000 -56,929,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -16,760,000 -56,929,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -16,760,000 -56,929,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -16,760,000 -56,929,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -16,760,000 -56,929,000
Operating Expenses UNPUB UNPUB 18,144,000 58,763,000
Operating Income/Loss UNPUB UNPUB -18,144,000 -58,763,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 0 0
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:PRLD240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:PRLD240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:PRLD240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:PRLD240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:PRLD240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:PRLD240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:PRLD240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:PRLD240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:PRLD240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:PRLD240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:PRLD240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:PRLD240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:PRLD240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:PRLD240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:PRLD240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:PRLD240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:PRLD240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:PRLD240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:PRLD240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:PRLD240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:PRLD240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:PRLD240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:PRLD240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:PRLD240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:PRLD240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:PRLD240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:PRLD240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:PRLD240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:PRLD240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:PRLD240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:PRLD231215P00015000 OPASPS Put American 100 15 BATO 2023-12-15
O:PRLD231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:PRLD231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:PRLD231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:PRLD231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:PRLD231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:PRLD231215C00015000 OCASPS Call American 100 15 BATO 2023-12-15
O:PRLD231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:PRLD231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:PRLD231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:PRLD231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:PRLD231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:PRLD231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:PRLD231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:PRLD231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:PRLD231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:PRLD231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:PRLD231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:PRLD231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:PRLD231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:PRLD231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:PRLD231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:PRLD231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:PRLD231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:PRLD230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:PRLD230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:PRLD230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:PRLD230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:PRLD230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:PRLD230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:PRLD230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:PRLD230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:PRLD230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:PRLD230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:PRLD230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:PRLD230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:PRLD230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:PRLD230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:PRLD230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:PRLD230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:PRLD230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:PRLD230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics to present preclinical data posters at the 2024 AACR on its oral SMARCA2 degrader, CDK9 inhibitor and next-gen CDK4/6 inhibitor
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics' Kris Vaddi and Jane Huang to participate in fireside chat at Barclay's Global Healthcare conference 2024 on March 13 in Miami
GlobeNewswire Inc. • 2mo ago
Analyst Analyst Ratings
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
Morgan Stanley downgraded its rating of Prelude Therapeutics (NASDAQ:PRLD) to Underweight with a price target of $4.00, changing its price target from $10.00 to $4.00. Shares of Prelude Therapeutics are trading up 0.0% over the last 24 hours, at $4.37 per share. A move to $4.00 would account for a 8.47% decrease from the current share price. About Prelude Therapeutics Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in ...Full story available on Benzinga.com
Benzinga • 5mo ago
Stocks Financing Agreements
Prelude Therapeutics Announces $25 Million Private Placement
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working capital and general corporate purposes.
GlobeNewswire Inc. • 5mo ago
Stocks Earnings Releases and Operating Results
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
GlobeNewswire Inc. • 6mo ago
Analyst Analyst Ratings
The Latest Analyst Ratings for Prelude Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Prelude Therapeutics (NASDAQ:PRLD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 2 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Prelude Therapeutics. The company has an average price target of $9.5 with a high of $17.00 and a low of $5.00. ...Full story available on Benzinga.com
Benzinga • 7mo ago
Calendar Calendar of Events
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude’s CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789.
GlobeNewswire Inc. • 7mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT